PL3746446T3 - Inhibitory PRC2 - Google Patents

Inhibitory PRC2

Info

Publication number
PL3746446T3
PL3746446T3 PL19710816.0T PL19710816T PL3746446T3 PL 3746446 T3 PL3746446 T3 PL 3746446T3 PL 19710816 T PL19710816 T PL 19710816T PL 3746446 T3 PL3746446 T3 PL 3746446T3
Authority
PL
Poland
Prior art keywords
prc2
inhibitors
prc2 inhibitors
Prior art date
Application number
PL19710816.0T
Other languages
English (en)
Inventor
Matthew Arnold Marx
Matthew Randolph Lee
Thomas P. Bobinski
Aaron Craig BURNS
Nidhi Arora
James Gail Christensen
John Michael Ketcham
Original Assignee
Mirati Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics, Inc. filed Critical Mirati Therapeutics, Inc.
Publication of PL3746446T3 publication Critical patent/PL3746446T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
PL19710816.0T 2018-01-31 2019-01-29 Inhibitory PRC2 PL3746446T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862624176P 2018-01-31 2018-01-31
US201862672701P 2018-05-17 2018-05-17
US201862747736P 2018-10-19 2018-10-19
PCT/US2019/015677 WO2019152419A1 (en) 2018-01-31 2019-01-29 Prc2 inhibitors

Publications (1)

Publication Number Publication Date
PL3746446T3 true PL3746446T3 (pl) 2022-08-29

Family

ID=65763738

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19710816.0T PL3746446T3 (pl) 2018-01-31 2019-01-29 Inhibitory PRC2

Country Status (18)

Country Link
US (4) US11485738B2 (pl)
EP (2) EP4043466A1 (pl)
JP (3) JP7025556B2 (pl)
KR (2) KR102451529B1 (pl)
CN (1) CN112004816B (pl)
AU (2) AU2019214861B2 (pl)
BR (1) BR112020015583B1 (pl)
CA (1) CA3089639A1 (pl)
DK (1) DK3746446T3 (pl)
ES (1) ES2923290T3 (pl)
HU (1) HUE059536T2 (pl)
IL (2) IL276156B (pl)
MX (2) MX2020007974A (pl)
NZ (1) NZ766447A (pl)
PL (1) PL3746446T3 (pl)
PT (1) PT3746446T (pl)
WO (1) WO2019152419A1 (pl)
ZA (2) ZA202004453B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112004816B (zh) 2018-01-31 2024-01-05 米拉蒂医疗股份有限公司 Prc2抑制剂
AU2019386036A1 (en) * 2018-11-30 2021-05-27 Tuojie Biotech (Shanghai) Co., Ltd. Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof
US20220274990A1 (en) * 2019-06-05 2022-09-01 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer
EP4019521A4 (en) * 2019-08-22 2023-05-03 Blueray Therapeutics (Shanghai) Co., Ltd AZAHETEROARYL COMPOUND AND USE
CN113004233B (zh) * 2019-12-18 2022-12-20 南京优氟医药科技有限公司 一种用于制备prc2抑制剂的化合物、其制备方法和用途
WO2023049724A1 (en) * 2021-09-24 2023-03-30 Oric Pharmaceuticals, Inc. Prc2 inhibitors for use in treating blood disorders
WO2024059607A1 (en) * 2022-09-14 2024-03-21 Oric Pharmaceuticals, Inc. Physical forms of an inhibitor of prc2

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921762B2 (en) * 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
WO2010021381A1 (ja) 2008-08-22 2010-02-25 武田薬品工業株式会社 縮合複素環誘導体およびその用途
UA110112C2 (uk) 2010-05-07 2015-11-25 Глаксосмітклайн Ллс Індоли
JP5864546B2 (ja) 2010-05-07 2016-02-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ インダゾール
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US9029343B2 (en) 2010-12-03 2015-05-12 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
EA028156B9 (ru) 2011-05-10 2018-01-31 Джилид Сайэнс, Инк. Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
RU2014117632A (ru) 2011-09-30 2015-11-10 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Способы лечения злокачественной опухоли
US9493501B2 (en) 2011-10-27 2016-11-15 Memorial Sloan-Kettering Cancer Center Methyltransferase inhibitors for treating cancer
EP2780014A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc METHYLATION MODIFICATION ENZYME MODULATORS, COMPOSITIONS AND USES THEREOF
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CA2862289C (en) 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CA2870010C (en) 2012-04-13 2023-02-21 Epizyme, Inc. Combination therapy for treating cancer
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
US9105490B2 (en) 2012-09-27 2015-08-11 Taiwan Semiconductor Manufacturing Company, Ltd. Contact structure of semiconductor device
JP6254169B2 (ja) 2012-09-28 2017-12-27 ファイザー・インク ベンズアミドおよびヘテロベンズアミド化合物
NZ706836A (en) 2012-10-15 2019-02-22 Epizyme Inc Methods of treating cancer
US9006242B2 (en) 2012-10-15 2015-04-14 Epizyme, Inc. Substituted benzene compounds
US9382234B2 (en) 2012-12-13 2016-07-05 Glaxosmithkline Llc Enhancer of Zeste Homolog 2 inhibitors
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
US9701666B2 (en) 2012-12-21 2017-07-11 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
EP2935214B1 (en) 2012-12-21 2019-02-20 Epizyme, Inc. 1,4-pyridone compounds
RS56207B1 (sr) 2013-02-11 2017-11-30 Constellation Pharmaceuticals Inc Modulatori enzima koji modifikuju metil, njihove kompozicije i upotreba
EP2970281A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED BENZENE COMPOUNDS
US9243001B2 (en) 2013-03-15 2016-01-26 Epizyme, Inc. Substituted benzene compounds
US9045477B2 (en) 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2970306A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS CONDENSED IN 6.5
EP2991980B1 (en) 2013-04-30 2019-01-02 Glaxosmithkline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors
AU2014276417B2 (en) 2013-06-06 2016-11-24 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of Zeste Homolog 2 inhibitors
JP2016523955A (ja) 2013-07-10 2016-08-12 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ Ｚｅｓｔｅホモログ２エンハンサー阻害剤
WO2015010049A1 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted benzene compounds
US9624205B2 (en) 2013-07-19 2017-04-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2015023915A1 (en) 2013-08-15 2015-02-19 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
WO2015077193A1 (en) 2013-11-19 2015-05-28 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
WO2015077194A1 (en) 2013-11-22 2015-05-28 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
EP3111222A1 (en) 2014-02-26 2017-01-04 Glaxosmithkline Intellectual Property (No. 2) Limited Methods of treating cancer patients responding to ezh2 inhibitor gsk126
EP3114125A1 (en) 2014-03-07 2017-01-11 Glaxosmithkline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors
PT3121175T (pt) 2014-03-17 2020-03-05 Daiichi Sankyo Co Ltd Derivados de 1,3-benzodioxol como inibidores de ezh1 e/ou ezh2
LT3157915T (lt) 2014-06-17 2019-04-25 Pfizer Inc. Pakeistieji dihidroizochinolino junginiai
WO2015193768A1 (en) 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
EP3212639A1 (en) 2014-10-28 2017-09-06 Glaxosmithkline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors
CA2964629A1 (en) 2014-11-06 2016-05-12 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
KR20170098808A (ko) 2014-11-06 2017-08-30 다나-파버 캔서 인스티튜트 인크. 이식편 대 숙주 질환 (gvhd)에 대한 염색질 구조를 조정하는 조성물의 용도
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ｅｚｈ２抑制劑
WO2016102493A1 (en) 2014-12-22 2016-06-30 Bayer Pharma Aktiengesellschaft Imidazopyridine ezh2 inhibitors
ME03385B (me) 2014-12-23 2020-01-20 Novartis Ag Triazolopirimidin jedinjenja i njihova upotreba
IL236420A (en) * 2014-12-23 2016-06-30 Ron Schneider Methods and systems for producing an enlarged 3D image
WO2016123387A1 (en) 2015-01-30 2016-08-04 Genentech, Inc. Therapeutic compounds and uses thereof
WO2016130396A1 (en) 2015-02-13 2016-08-18 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
DK3378859T3 (da) 2015-11-19 2020-01-20 Jiangsu Hengrui Medicine Co Benzofuranderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i medicin
JP2018536009A (ja) 2015-12-07 2018-12-06 エピザイム，インコーポレイティド Ｅｚｈ２の阻害剤およびその使用の方法
WO2017174023A1 (zh) 2016-04-08 2017-10-12 南京明德新药研发股份有限公司 作为ezh2抑制剂的联苯化合物
CN109069508A (zh) 2016-04-22 2018-12-21 达纳-法伯癌症研究所股份有限公司 Ezh2抑制剂及其用途
PE20190106A1 (es) 2016-05-05 2019-01-15 Glaxosmithkline Ip No 2 Ltd Inhibidores del potenciador del homologo zeste 2
US9957274B2 (en) 2016-05-06 2018-05-01 Abbvie Inc. Indane inhibitors of EED and methods of their use
CA3025933A1 (en) 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
JP2019521988A (ja) 2016-06-17 2019-08-08 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤
US10689378B2 (en) 2016-06-20 2020-06-23 Novartis Ag Triazolopyridine compounds and uses thereof
CN109790166A (zh) * 2016-06-20 2019-05-21 诺华股份有限公司 咪唑并吡啶化合物用于治疗癌症
US11091489B2 (en) 2016-06-20 2021-08-17 Novartis Ag Crystalline forms of a triazolopyrimidine compound
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
WO2019062435A1 (zh) 2017-09-28 2019-04-04 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
CN109942556A (zh) 2017-12-21 2019-06-28 上海青煜医药科技有限公司 嘧啶酮化合物及其应用
CN112004816B (zh) 2018-01-31 2024-01-05 米拉蒂医疗股份有限公司 Prc2抑制剂
CN110156787B (zh) 2018-02-13 2021-11-02 中国科学院上海药物研究所 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途
CN110563722A (zh) 2018-06-06 2019-12-13 上海青煜医药科技有限公司 吡啶或哒嗪并环化合物及其应用
JP2022530866A (ja) 2019-04-22 2022-07-04 ミラティ セラピューティクス，インク． Ｐｒｃ２阻害剤としてのナフチリジン誘導体
US20220274990A1 (en) 2019-06-05 2022-09-01 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer

Also Published As

Publication number Publication date
JP7025556B2 (ja) 2022-02-24
US20210230168A1 (en) 2021-07-29
ZA202107835B (en) 2022-07-27
CA3089639A1 (en) 2019-08-08
AU2021266351A1 (en) 2021-12-09
ES2923290T3 (es) 2022-09-26
EP3746446B1 (en) 2022-05-11
AU2021266351B2 (en) 2022-11-24
AU2019214861A1 (en) 2020-08-13
WO2019152419A1 (en) 2019-08-08
JP2023109962A (ja) 2023-08-08
EP3746446A1 (en) 2020-12-09
US20230137025A1 (en) 2023-05-04
MX2020007974A (es) 2020-09-07
JP2022068252A (ja) 2022-05-09
KR20200115570A (ko) 2020-10-07
MX2021012501A (es) 2021-11-12
US20210032252A1 (en) 2021-02-04
KR102451529B1 (ko) 2022-10-06
NZ766447A (en) 2021-12-24
IL276156B (en) 2021-08-31
BR112020015583B1 (pt) 2022-12-06
US11091495B2 (en) 2021-08-17
IL285354A (en) 2021-09-30
US11485738B2 (en) 2022-11-01
AU2019214861B2 (en) 2021-11-18
KR20220139439A (ko) 2022-10-14
IL276156A (en) 2020-09-30
JP2021512092A (ja) 2021-05-13
WO2019152419A8 (en) 2019-11-07
EP4043466A1 (en) 2022-08-17
US11220509B2 (en) 2022-01-11
US20210101904A1 (en) 2021-04-08
PT3746446T (pt) 2022-07-18
CN112004816B (zh) 2024-01-05
CN112004816A (zh) 2020-11-27
DK3746446T3 (da) 2022-06-27
HUE059536T2 (hu) 2022-11-28
JP7288527B2 (ja) 2023-06-07
IL285354B (en) 2022-06-01
BR112020015583A2 (pt) 2021-02-02
ZA202004453B (en) 2022-11-30

Similar Documents

Publication Publication Date Title
IL283639A (en) kif18a inhibitors
PL3793565T3 (pl) Inhibitory MCL-1
IL277006A (en) CD73 inhibitors
IL269196A (en) New inhibitors
ZA202107835B (en) Prc2 inhibitors
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
IL304348A (en) cd73 inhibitors
IL276813A (en) Arginase inhibitors
SG11202010347XA (en) Stat3 inhibitors
GB201807014D0 (en) Factor xlla inhibitors
ZA201907136B (en) Ip6k inhibitors
IL276013A (en) pi4kiiibeta inhibitors
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors
IL274550A (en) Dopamine-B-hydroxylase inhibitors
GB201807845D0 (en) Kinase Inhibitors
GB201812462D0 (en) Inhibitors
GB201804439D0 (en) Dopamin-b-hydroxylase inhibitors
GB201908044D0 (en) Dopamine-B-Hydroxylase inhibitors
GB201905476D0 (en) MAPA4K4 Inhibitors
GB201809939D0 (en) Eastase inhibitor
GB201721465D0 (en) Inhibitors
GB201720189D0 (en) Dopamine-B-hydroxylase inhibitors